The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The clinical outcomes and QoL after treatment with ide-cel in older patients with myeloma
Krina Patel, MD, MSc, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on a recent publication investigating the real-world outcomes of older patients (65 years and above) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel). This real-world experience highlighted that older patients, even those with polypharmacy due to a host of comorbidities, can safely receive ide-cel CAR T-cell therapy, and the treatment significantly improves their quality of life (QoL). This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
